Treatment of cancer using a combination of immunomodulation and check point inhibitors
AssigneeAngimmune, LLC
InventorsDavid M. Neville, Yuan Yi Liu
Life of this patent
Estimating the term…
Abstract
Methods of treating patients suffering from cancer using a combination of 1) an immunomodulatory agent; 2) a check point inhibitor; and 3) a cancer antigen releasing therapy are provided. In some aspects, the immunomodulatory agent is an anti-CD3 immunotoxin, the check point inhibitor inhibits the interaction of PD-1 and PD-L1 and the cancer antigen releasing therapy is radiation.
Claims12
A method of treating a cancer in a subject in need thereof, comprising administering an anti-CD3 specific immunotoxin to the subject in an amount sufficient to deplete extant T-cells of the subject,
- providing to the subject a therapy that releases cancer antigens expressed by the cancer, and
- administering a check point inhibitor to the subject,
- wherein depletion of the extant T-cells of the patient causes repopulation and maturation of new T cells in the patient in the presence of the cancer antigens.
A method of lengthening survival time of a patient suffering from a cancer comprising
- administering an anti-CD3 specific immunotoxin to the patient in an amount sufficient to deplete extant T-cells of the patient,
- providing a therapy that releases cancer antigens expressed by the cancer to the patient, and
- administering a check point inhibitor to the patient,
- wherein depletion of the extant T-cells of the patient causes repopulation and maturation of new T cells in the patient in the presence of the cancer antigens, thereby lengthening the survival time of the patient.
A method of increasing the overall response rate of a subject suffering from a metastatic and or recurrent cancer by preparing the immune system of a patient to recognize and kill metastatic and/or recurrent cancer, comprising
- administering an anti-CD3 specific immunotoxin to the patient in an amount sufficient to deplete extant T-cells of the patient,
- administering a check point inhibitor to the patient, and
- providing radiation therapy to one metastatic lesion that releases cancer antigens expressed by the cancer to the patient,
- wherein depletion of the extant T-cells of the patient causes repopulation and maturation of new T cells in the patient in the presence of the cancer antigens, thereby preparing the immune system of a patient to recognize and kill metastatic and/or recurrent cancer by a factor of at least 135% over the administration of the check point inhibitor alone (without anti-CD3 specific immunotoxin and without radiation therapy to one metastatic lesion).
Dependencies are inferred from the claim text.